Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Feb 3;12(2):e0171608.
doi: 10.1371/journal.pone.0171608. eCollection 2017.

Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis

Li-Hong Shou  1 , Dan Cao  1 , Xiao-Hui Dong  1 , Qiu Fang  1 , Ying Wu  1 , Yan Zhang  1 , Ju-Ping Fei  1 , Bao-Lian Xu  1
Affiliations
Meta-Analysis

Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis

Li-Hong Shou et al. PLoS One. .

Abstract

Objectives: This meta-analysis investigates the prognostic effect of SET binding protein 1 (SETBP1) mutations in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or chronic neutrophilic leukemia (CNL).

Methods: Eligible studies from Pubmed, Embase, and Web of Science were searched from database inception through April 2016. Hazard ratios (HRs) and 95% confidence interval (CI) of overall survival (OS) were pooled to calculate the prognostic significance of SETBP1 mutation in patients.

Results: A total of 12 studies with 2321 patients were included in this meta-analysis; 4 studies for MDS, 5 studies for CMML, and 3 studies for CNL. Pooled results suggested that MDS and CMML patients with SETBP1 mutations had a significantly poorer prognosis when compared with patients with wild-type SETBP1 (MDS: HR = 1.808, 95% CI (1.218-2.685), P = 0.001; CMML: HR = 2.223, 95% CI (1.493-3.308), P<0.001). SETBP1 mutations in CNL patients however, showed no significant effect on the overall survival (HR = 1.773, 95% CI (0.877-3.582), P = 0.111). The Begg's and Egger's tests did not show significant publication bias in any groups.

Conclusions: Current evidence shows that SETBP1 mutation is associated with a poor prognosis in patients with MDS and CMML, but not in patients with CNL.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart of study selection.
Fig 2
Fig 2. Forest plot of the HR and 95% CI for OS in MDS patients.
Fig 3
Fig 3. Sensitivity analysis for all included MDS studies.
Fig 4
Fig 4. Begg’s funnel plot of the prognostic significance of SETBP1 mutation in MDS patients.
Fig 5
Fig 5. Forest plot of the HR and 95% CI for OS in CMML patients.
Fig 6
Fig 6. Sensitivity analysis for all included CMML studies.
Fig 7
Fig 7. Begg’s funnel plot of the prognostic significance of SETBP1 mutation in CMML patients.
Fig 8
Fig 8. Forest plot of the HR and 95% CI for OS in CNL patients.
Fig 9
Fig 9. Sensitivity analysis for all included CNL studies.
Fig 10
Fig 10. Begg’s funnel plot of the prognostic significance of SETBP1 mutation in CNL patients.
See this image and copyright information in PMC

References

    1. Cristobal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood. 2010;115(3):615–25. Epub 2009/12/08. 10.1182/blood-2009-06-227363 - DOI - PubMed
    1. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18–24. Epub 2012/12/12. 10.1038/ng.2495 - DOI - PMC - PubMed
    1. Hoischen A, van Bon BW, Gilissen C, Arts P, van Lier B, Steehouwer M, et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat Genet. 2010;42(6):483–5. 10.1038/ng.581 - DOI - PubMed
    1. Schinzel A, Giedion A. A syndrome of severe midface retraction, multiple skull anomalies, clubfeet, and cardiac and renal malformations in sibs. Am J Med Genet. 1978;1(4):361–75. 10.1002/ajmg.1320010402 - DOI - PubMed
    1. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013;45(8):942–6. Epub 2013/07/09. 10.1038/ng.2696 - DOI - PMC - PubMed

Publication types

MeSH terms